Philip J Barter

Summary

Affiliation: The Heart Research Institute
Country: Australia

Publications

  1. ncbi Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells
    Philip J Barter
    Lipid Research Laboratory, Hanson Institute for Medical Research, Adelaide, Australia
    Curr Opin Lipidol 13:285-8. 2002
  2. ncbi Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?
    Philip J Barter
    Circulation 113:1553-5. 2006
  3. ncbi Relationship between the concentration and antiatherogenic activity of high-density lipoproteins
    Philip J Barter
    The Heart Research Institute, Sydney, Australia
    Curr Opin Lipidol 17:399-403. 2006
  4. ncbi Homocysteine and cardiovascular disease: is HDL the link?
    Philip J Barter
    Circ Res 99:565-6. 2006
  5. doi Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment
    Gilles Lambert
    The Heart Research Institute, Sydney, Australia
    Clin Chem 54:1038-45. 2008
  6. ncbi Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease
    Philip J Barter
    The Heart Research Institute, Camperdown, Sydney, Australia
    J Am Coll Cardiol 47:492-9. 2006
  7. ncbi Managing diabetic dyslipidaemia--beyond LDL-C:HDL-C and triglycerides
    Philip Barter
    The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
    Atheroscler Suppl 7:17-21. 2006
  8. ncbi The inflammation: lipoprotein cycle
    Philip Barter
    The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
    Atheroscler Suppl 6:15-20. 2005
  9. ncbi Antiinflammatory properties of HDL
    Philip J Barter
    The Heart Research Institute, 145 Missenden Rd, Camperdown, Sydney 2050, Australia
    Circ Res 95:764-72. 2004
  10. ncbi Metabolic abnormalities: high-density lipoproteins
    Philip Barter
    The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney NSW 2050, Australia
    Endocrinol Metab Clin North Am 33:393-403. 2004

Collaborators

Detail Information

Publications69

  1. ncbi Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells
    Philip J Barter
    Lipid Research Laboratory, Hanson Institute for Medical Research, Adelaide, Australia
    Curr Opin Lipidol 13:285-8. 2002
    ..The mechanism of this potentially anti-atherogenic effect of HDLs remains uncertain, as does its contribution to the cardioprotective effects of HDLs in vivo...
  2. ncbi Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?
    Philip J Barter
    Circulation 113:1553-5. 2006
  3. ncbi Relationship between the concentration and antiatherogenic activity of high-density lipoproteins
    Philip J Barter
    The Heart Research Institute, Sydney, Australia
    Curr Opin Lipidol 17:399-403. 2006
    ..The relationship between the concentration of high-density lipoprotein cholesterol and their protective function is addressed...
  4. ncbi Homocysteine and cardiovascular disease: is HDL the link?
    Philip J Barter
    Circ Res 99:565-6. 2006
  5. doi Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment
    Gilles Lambert
    The Heart Research Institute, Sydney, Australia
    Clin Chem 54:1038-45. 2008
    ..Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the LDL receptor (LDLr) in hepatocytes, and its expression in mouse liver has been shown to decrease with fenofibrate treatment...
  6. ncbi Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease
    Philip J Barter
    The Heart Research Institute, Camperdown, Sydney, Australia
    J Am Coll Cardiol 47:492-9. 2006
    ..Larger, long-term, randomized, clinical end point trials are required to determine whether the beneficial effects of CETP inhibitors on lipoprotein metabolism can translate into reductions in cardiovascular events...
  7. ncbi Managing diabetic dyslipidaemia--beyond LDL-C:HDL-C and triglycerides
    Philip Barter
    The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
    Atheroscler Suppl 7:17-21. 2006
    ....
  8. ncbi The inflammation: lipoprotein cycle
    Philip Barter
    The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
    Atheroscler Suppl 6:15-20. 2005
    ..Additional protection from atherosclerosis may be provided by novel therapies that aim to increase plasma levels and activity of HDLs...
  9. ncbi Antiinflammatory properties of HDL
    Philip J Barter
    The Heart Research Institute, 145 Missenden Rd, Camperdown, Sydney 2050, Australia
    Circ Res 95:764-72. 2004
    ..These antioxidant and antiinflammatory properties of HDL may be as important as its cholesterol efflux function in terms of protecting against the development of atherosclerosis...
  10. ncbi Metabolic abnormalities: high-density lipoproteins
    Philip Barter
    The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney NSW 2050, Australia
    Endocrinol Metab Clin North Am 33:393-403. 2004
    ..The consequences of a low HDL concentration in this syndrome are addressed before the article concludes with a discussion of whether low HDL in the metabolic syndrome should be a therapeutic target...
  11. ncbi HDL: a recipe for longevity
    Philip Barter
    The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
    Atheroscler Suppl 5:25-31. 2004
    ..As data accumulate on the protective role of HDLs, there is growing support for interventions that act to raise HDL-C concentrations...
  12. ncbi Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis
    Philip J Barter
    Hanson Institute and the Department of Cardiology, Royal Adelaide Hospital, Adelaide, Australia
    Arterioscler Thromb Vasc Biol 23:160-7. 2003
    ..Thus, it seems important and timely to test the hypothesis in randomized trials of humans that pharmacological inhibition of CETP retards the development of atherosclerosis...
  13. pmc The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro
    Fatiha Tabet
    Lipid Research Group, Heart Research Institute, Sydney, New South Wales, Australia
    Arterioscler Thromb Vasc Biol 30:246-52. 2010
    ..The effects of the 5A/PLPC complex were no longer apparent in HCAECs knocked down for ABCA1...
  14. pmc Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I
    Estelle Nobecourt
    Lipid Research Group, The Heart Research Institute, Sydney, New South Wales, Australia
    Arterioscler Thromb Vasc Biol 30:766-72. 2010
    ..The goal of this study was to investigate the effects of nonenzymatic glycation on the antiinflammatory properties of apolipoprotein (apo) A-I...
  15. doi Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins
    Sanjay Patel
    The Heart Research Institute, Sydney, Australia
    Atherosclerosis 204:424-8. 2009
    ..In this study, the influence of acute hypertriglyceridaemia on the composition and anti-inflammatory properties of HDL was investigated...
  16. doi The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins
    Belinda A Di Bartolo
    Lipid Research Group, Heart Research Institute, Sydney, Australia
    Atherosclerosis 217:395-400. 2011
    ..This study aimed to compare the anti-inflammatory effects of ETC-642, a new apoA-I mimetic peptide, with discoidal reconstituted HDL (rHDL)...
  17. doi Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion
    Michelle A Fryirs
    The Heart Research Institute, Sydney, New South Wales, Australia
    Arterioscler Thromb Vasc Biol 30:1642-8. 2010
    ..Given the current interest in therapeutic interventions that raise HDLs levels, this study investigates the effects of HDLs on insulin secretion from beta-cells...
  18. doi High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo
    Christina A Bursill
    Heart Research Institute, 7 Eliza St, Sydney, New South Wales 2042, Australia
    Arterioscler Thromb Vasc Biol 30:1773-8. 2010
    ..To investigate whether high-density lipoproteins (HDLs) suppress chemokine (CCL2, CCL5, and CX(3)CL1) and chemokine receptor (CCR2 and CX(3)CR1) expression, a mechanism for the atheroprotective properties of HDLs...
  19. ncbi Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo
    Rajesh Puranik
    The Heart Research Institute, Lipid Research Group 145, Missenden Road, Sydney, NSW 2050, Australia
    Atherosclerosis 196:240-7. 2008
    ..These findings have potential implications for treating acute vascular inflammation in conditions such as acute coronary and stroke syndromes...
  20. ncbi Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I
    Kerry Anne Rye
    Heart Research Institute, Camperdown, Sydney, NSW, Australia
    Arterioscler Thromb Vasc Biol 24:421-8. 2004
    ..This review describes current knowledge regarding the formation, metabolism, and regulation of monomolecular, lipid-free/lipid-poor apoA-I in plasma...
  21. doi Trends in C-reactive protein levels in US adults from 1999 to 2010
    Kwok Leung Ong
    Lipid Research Group, Heart Research Institute, Sydney, New South Wales, Australia
    Am J Epidemiol 177:1430-42. 2013
    ..Such trends may be explained in part by the increasing use of medications such as statins, which can increase bilirubin levels and decrease CRP levels...
  22. doi Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages
    Fatiha Tabet
    Lipid Research Group, The Heart Research Institute, 7 Eliza Street, Sydney, New South Wales 2042, Australia
    Arterioscler Thromb Vasc Biol 31:1192-200. 2011
    ....
  23. ncbi Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit
    Neil J Hime
    Lipid Research Group, The Heart Research Institute, Camperdown, Sydney, New South Wales 2050, Australia
    J Lipid Res 47:115-22. 2006
    ..We conclude that, irrespective of the form in which apoA-II enters the plasma, it is rapidly incorporated into spherical HDLs that also contain apoA-I to form (A-I/A-II)HDL...
  24. ncbi Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits
    Stephen J Nicholls
    Heart Research Institute, Sydney, Australia
    Circulation 111:1543-50. 2005
    ..HDLs have antiinflammatory and antioxidant properties in vitro. This study investigates these properties in vivo...
  25. ncbi N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteins
    Danielle Skropeta
    Lipid Research Group, Heart Research Institute, Camperdown, New South Wales 2050, Australia
    J Lipid Res 48:2047-57. 2007
    ..These data show that individual N-linked glycans have unique and important effects on the phospholipase activity and substrate specificity of EL...
  26. doi Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial
    Philip J Barter
    The Heart Research Institute, Sydney, Australia
    Circulation 124:555-62. 2011
    ..We now investigate effects on glucose homeostasis of inhibiting cholesteryl ester transfer protein with torcetrapib...
  27. ncbi Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein
    Nongnuch Settasatian
    Lipid Research Group, Heart Research Institute, Sydney, New South Wales 2050, Australia
    J Lipid Res 49:115-26. 2008
    ..It is concluded that apoE enhances the capacity of PLTP to remodel HDL but reduces the ability of HDL to participate in PLTP-mediated phospholipid transfers...
  28. ncbi Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E
    Kerry Anne Rye
    Lipid Research Group, The Heart Research Institute, Camperdown, Sydney, New South Wales, Australia
    J Lipid Res 47:1025-36. 2006
    ....
  29. ncbi Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits
    Stephen J Nicholls
    The Heart Research Institute, Sydney, Australia
    Arterioscler Thromb Vasc Biol 25:2416-21. 2005
    ..Effects of HDL apolipoprotein and phospholipid composition have also been investigated...
  30. ncbi Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation
    Kerry Anne Rye
    Lipid Research Laboratory, Hanson Institute, Adelaide, South Australia 5000, Australia
    J Biol Chem 278:22530-6. 2003
    ....
  31. pmc Relationship between atorvastatin dose and the harm caused by torcetrapib
    Philip J Barter
    The Heart Research Institute, Sydney, Australia
    J Lipid Res 53:2436-42. 2012
    ..The harm could not be explained by torcetrapib-induced changes in lipid levels, blood pressure, or electrolytes. It is conceivable that higher doses of atorvastatin protected against the harm caused by torcetrapib...
  32. doi High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3β-hydroxysteroid-Δ24 reductase expression and inducing heme oxygenase-1
    Ben J Wu
    Lipid Research Group, The Heart Research Institute, 7 Eliza St, Newtown, Sydney, New South Wales 2042, Australia
    Circ Res 112:278-88. 2013
    ..Lipid-free apolipoprotein (apo) A-I and discoidal reconstituted high-density lipoproteins (rHDL) containing apoA-I, (A-I)rHDL, inhibit vascular inflammation by increasing 3β-hydroxysteroid-Δ24 reductase (DHCR24) expression...
  33. ncbi High-density lipoproteins as therapeutic targets
    Stephen J Nicholls
    The Heart Research Institute, Sydney, Australia
    Curr Opin Lipidol 16:345-9. 2005
    ..The best known antiatherogenic function of HDL particles relates to their ability to promote the efflux of cholesterol from cells. However, they also have antioxidant, antiinflammatory and antithrombotic properties...
  34. doi Anti-inflammatory effects of apolipoprotein A-I in the rabbit
    Sanjay Patel
    Lipid Research Group, The Heart Research Institute, Sydney, NSW 2042, Australia
    Atherosclerosis 212:392-7. 2010
    ..The present study asks if this benefit is related to an improved anti-inflammatory capacity of the high-density lipoprotein (HDL) fraction, or to increased arterial expression of genes that inhibit inflammation...
  35. ncbi High-density lipoproteins neutralize C-reactive protein proinflammatory activity
    Carol Wadham
    Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
    Circulation 109:2116-22. 2004
    ..CONCLUSIONS: The CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components...
  36. ncbi New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease
    Philip J Barter
    The Heart Research Institute, 114 Pyrmont Bridge Road, Camperdown, Sydney 2050, Australia
    Curr Cardiol Rep 9:493-8. 2007
    ..These results have potentially important clinical implications in regard to managing the acute vascular inflammation states that accompany acute coronary syndrome and acute ischemic stroke...
  37. ncbi Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent manner
    Neil J Hime
    Lipid Research Group, The Heart Research Institute, Camperdown, Sydney, New South Wales, Australia
    Biochemistry 43:12306-14. 2004
    ..These results show that apoE increases the rate of HL-mediated phospholipid and triacylglycerol hydrolysis in rHDL and that this influence is isoform dependent...
  38. ncbi Effects of torcetrapib in patients at high risk for coronary events
    Philip J Barter
    Heart Research Institute, Camperdown, Sydney, NSW, Australia
    N Engl J Med 357:2109-22. 2007
    ..We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib...
  39. ncbi High-density lipoproteins enhance progenitor-mediated endothelium repair in mice
    Colin Tso
    Heart Research Institute, Sydney, NSW 2050, Australia
    Arterioscler Thromb Vasc Biol 26:1144-9. 2006
    ..Studies were conducted in C57BL/6J and in apolipoprotein E-deficient (apoE(-/-)) mice. We also investigated the possibility that high-density lipoproteins (HDL) may promote progenitor-mediated endothelial repair...
  40. ncbi Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function
    Stephen J Nicholls
    The Heart Research Institute, Sydney, Australia
    J Am Coll Cardiol 48:715-20. 2006
    ..The purpose of this study was to investigate the influence of dietary fatty acids on the anti-inflammatory properties of high-density lipoproteins (HDL) and vascular function...
  41. doi Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I
    Gerrit J Reimers
    The Heart Research Institute, 7 Eliza Street, Newtown NSW 2042, Australia
    Cardiovasc Res 91:37-44. 2011
    ..We investigated the effect of treatment with human apolipoprotein A-I (apoA-I), the principal protein of HDL, on plaque disruption in an animal model...
  42. doi Arthritis: its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008
    Kwok Leung Ong
    Lipid Research Group, Heart Research Institute, Sydney, New South Wales, Australia
    Ann Epidemiol 23:80-6. 2013
    ..However, there are limited epidemiologic studies on arthritis in a national survey study. We therefore investigated the prevalence of self-reported arthritis and its association with CVDs...
  43. doi Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes
    Kwok Leung Ong
    Lipid Research Group, Heart Research Institute, Sydney, New South Wales 2042, Australia
    J Clin Endocrinol Metab 97:4701-8. 2012
    ....
  44. doi Niacin inhibits vascular inflammation via the induction of heme oxygenase-1
    Ben J Wu
    Lipid Research Group, The Heart Research Institute, 7 Eliza St, Newtown, NSW, Australia, 2042
    Circulation 125:150-8. 2012
    ..This study asks if the cardioprotective properties of niacin involve the induction of HO-1...
  45. doi Cholesterol metabolism and pancreatic beta-cell function
    Michelle Fryirs
    Lipid Research Group, The Heart Research Institute, New South Wales, Australia
    Curr Opin Lipidol 20:159-64. 2009
    ..This review summarizes recent advances in understanding the relationship between beta-cell cholesterol metabolism and beta-cell function...
  46. ncbi Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
    Philip J Barter
    The Heart Research Institute, Sydney, Australia 2050
    Arterioscler Thromb Vasc Biol 28:39-46. 2008
    ..It remains to be determined whether the combination of a fibrate plus statin reduces the risk beyond that achieved with a statin alone...
  47. doi Predictive value of different HDL particles for the protection against or risk of coronary heart disease
    Kerry Anne Rye
    Lipid Research Group, The Heart Research Institute, Sydney, NSW, Australia
    Biochim Biophys Acta 1821:473-80. 2012
    ..This article is part of a Special Issue entitled Advances in High Density Lipoprotein Formation and Metabolism: A Tribute to John F. Oram (1945-2010)...
  48. pmc Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database
    Philip J Barter
    Heart Research Institute, Sydney, Australia
    J Lipid Res 51:1546-53. 2010
    ..The HDL-C increase achieved by all three statins was independent of LDL-C decrease. However, baseline HDL-C and TGs and the presence of diabetes were predictors of statin-induced increases in HDL-C...
  49. ncbi Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins
    Philip J Barter
    The Heart Research Institute and the Department of Medicine, University of Sydney, Australia
    Circulation 114:1315-20; discussion 1320. 2006
  50. ncbi Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia
    Philip Barter
    The Heart Research Institute, Camperdown, New South Wales, Australia
    J Clin Endocrinol Metab 92:2041-5. 2007
    ..The worldwide epidemic of overweight and obesity is setting the scene for a new wave of premature cardiovascular disease...
  51. doi Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial
    Philip Barter
    The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, New South Wales, Australia 2042
    Am J Cardiol 104:10E-5E. 2009
    ..The potential of CETP inhibition to reduce cardiovascular risk will be determined by the outcome of ongoing clinical trials with CETP inhibitors that do not share the off-target effects of torcetrapib...
  52. ncbi HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
    Philip Barter
    Heart Research Institute, Sydney, Australia
    N Engl J Med 357:1301-10. 2007
    ..High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol...
  53. ncbi Are we lowering LDL cholesterol sufficiently?
    Philip Barter
    The Heart Research Institute, Sydney, NSW, Australia
    Nat Clin Pract Cardiovasc Med 3:290-1. 2006
  54. pmc Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
    Philip J Barter
    The Heart Research Institute, Sydney, New South Wales, 2042, Australia
    J Lipid Res 53:1755-66. 2012
    ....
  55. doi Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999-2008
    Kwok Leung Ong
    Lipid Research Group, Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW 2042, Australia
    Atherosclerosis 219:728-33. 2011
    ..As statins can stimulate heme oxygenase-1 (HO-1), which increases bilirubin production, we investigated whether statins in routine use increase total bilirubin levels in subjects at high cardiovascular risk...
  56. ncbi Metabolism of apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits
    Patrick Kee
    University Department of Medicine, Royal Adelaide Hospital, Adelaide, Australia
    Arterioscler Thromb Vasc Biol 22:1912-7. 2002
    ..This study investigates (1) the in vivo metabolism of apoA-I in each of these forms and (2) the effects of hepatic lipase (HL) on apoA-I metabolism...
  57. pmc The metabolism and anti-atherogenic properties of HDL
    Kerry Anne Rye
    Lipid Research Group, The Heart Research Institute, Sydney, NSW, Australia
    J Lipid Res 50:S195-200. 2009
    ..This review documents what is known about the relationship between the metabolism and function of HDL subpopulations and how this affects their cardioprotective properties...
  58. pmc Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia
    Philip Barter
    Heart Research Institute, Camperdown, Sydney, New South Wales, Australia
    Am J Cardiol 102:1040-5. 2008
    ..In conclusion, several classes of drugs, including omega-3 fatty acids, can be used in combination with statins to achieve more global improvements in lipid profiles...
  59. doi Regulation of high-density lipoprotein metabolism
    Kerry Anne Rye
    From the Lipid Research Group, Centre for Vascular Research, Lowy Center, University of New South Wales, Sydney, New South Wales, Australia
    Circ Res 114:143-56. 2014
    ..This review provides an overview of what is currently understood about HDL metabolism and how the subpopulation distribution of these lipoproteins is regulated. ..
  60. ncbi High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions
    Philip Barter
    Cardiovascular Investigation Unit, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia
    Atherosclerosis 168:195-211. 2003
    ..This review summarises what is known and highlights what we still need to know...
  61. ncbi Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodeling
    Kerry Anne Rye
    Lipid Research Laboratory, Hanson Institute, Adelaide, South Australia, Australia 5000
    Biochemistry 41:12538-45. 2002
    ..In conclusion, these results show that phospholipids play a key role in the CETP-mediated remodeling of rHDL and pre-beta apoA-I formation...
  62. ncbi Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study
    Herbert Schuster
    Humboldt University, Berlin, Germany
    Am Heart J 147:705-13. 2004
    ....
  63. doi Antiinflammatory actions of HDL: a new insight
    Kerry Anne Rye
    Arterioscler Thromb Vasc Biol 28:1890-1. 2008
  64. ncbi Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids
    MyNgan Duong
    Department of Medicine, University of Adelaide, North Terrace, Australia
    Biochemistry 42:13778-85. 2003
    ..These results establish that EL and HL have different substrate specificities for rHDL phospholipids and that their interactions with the rHDL surface are regulated by phospholipids...
  65. ncbi Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia
    John J P Kastelein
    Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    N Engl J Med 356:1620-30. 2007
    ..Torcetrapib, an inhibitor of cholesteryl ester transfer protein, may reduce atherosclerotic vascular disease by increasing levels of high-density lipoprotein (HDL) cholesterol...
  66. ncbi Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
    Vivienne M Homer
    Canterbury Health Laboratories, 8001 Christchurch, New Zealand
    Atherosclerosis 196:659-66. 2008
    ..Our study therefore indicates that PCSK9 mediated inhibition of the LDLR does not require PCSK9 autocatalytic cleavage or secretion, suggesting that PCSK9 may also function intracellularly...
  67. ncbi Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia
    Yi Yu
    Department of Medicine Genetics Program, Boston University School of Medicine, Boston, MA, USA
    J Lipid Res 46:2202-13. 2005
    ..These data also indicate that a large proportion of the variance of TG levels in the Turkish population is explained by the interaction of multiple genetic loci...
  68. ncbi Coronary plaque regression: role of low density lipoprotein-apheresis
    Philip J Barter
    J Am Coll Cardiol 40:228-30. 2002
  69. ncbi Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project)
    Diego F Wyszynski
    Department of Medicine Genetics Program, Boston University School of Medicine, Boston, MA, USA
    Am J Cardiol 95:194-8. 2005
    ..In subjects aged <35 years, atherogenic dyslipidemia frequently occurs in the absence of other metabolic syndrome risk factors...